Zafgen, Inc. (NASDAQ:ZFGN) has been given an average recommendation of “Hold” by the five analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $9.00.
A number of equities analysts have weighed in on ZFGN shares. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Wednesday, May 10th. Roth Capital began coverage on shares of Zafgen in a research report on Thursday, April 20th. They issued a “buy” rating and a $9.00 target price for the company. Finally, ValuEngine upgraded shares of Zafgen from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th.
Shares of Zafgen (NASDAQ ZFGN) traded up 0.89% during mid-day trading on Tuesday, reaching $3.39. 68,131 shares of the company’s stock were exchanged. The stock’s market capitalization is $92.79 million. Zafgen has a 1-year low of $2.89 and a 1-year high of $5.46. The company’s 50 day moving average is $3.57 and its 200 day moving average is $4.12.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. Equities research analysts anticipate that Zafgen will post ($2.34) EPS for the current fiscal year.
In other Zafgen news, insider Dennis D. Kim bought 10,000 shares of Zafgen stock in a transaction dated Thursday, May 11th. The stock was acquired at an average cost of $4.40 per share, for a total transaction of $44,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 21.20% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the stock. LMR Partners LLP acquired a new stake in shares of Zafgen during the second quarter worth approximately $299,000. Algert Global LLC acquired a new stake in shares of Zafgen during the second quarter worth approximately $123,000. Spark Investment Management LLC boosted its stake in shares of Zafgen by 49.5% in the second quarter. Spark Investment Management LLC now owns 282,200 shares of the biopharmaceutical company’s stock worth $990,000 after buying an additional 93,500 shares during the period. Acadian Asset Management LLC purchased a new stake in Zafgen during the second quarter valued at about $304,000. Finally, Paloma Partners Management Co boosted its stake in Zafgen by 17.4% in the first quarter. Paloma Partners Management Co now owns 130,000 shares of the biopharmaceutical company’s stock valued at $606,000 after buying an additional 19,278 shares during the last quarter. Institutional investors and hedge funds own 52.35% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
